Robert P. Lisak, M.D., FAAN, FRCP served as Professor and Chair of the Department of Neurology as well Neurologist-in-Chief of the Detroit Medical Center from 1987-2012. He previously was a member of the Department of Neurology, the Graduate Group in Immunology and an Associate Member of the Neuroscience Institute at the University of Pennsylvania, where he also served as Vice-Chair of Neurology. Having served on multiple editorial boards, Dr. Lisak is the Editor of the Journal of the Neurological Sciences, the journal of the World Federation of Neurology.
Dr. Lisak’s research and clinical interests are in autoimmune/immunological mediated diseases of the nervous system including multiple sclerosis and related disorders, myasthenia gravis, inflammatory neuropathies including Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathies, inflammatory myopathies, CNS vasculitis and neurological complications of system autoimmune diseases such as systemic lupus erythematosis, Sjogren’s syndrome, rheumatoid arthritis, mixed connective tissue disease and others. His research studies include basic science, clinical research including treatment trials and translational research. Over the years his work has been funded by the National Institutes of Health, the National Multiple Sclerosis Society, the Muscular Dystrophy Association, the Guillain-Barre Syndrome/CIDP Foundation, the Myasthenia Gravis Foundation of America as well as by philanthropy and pharmaceutical companies.
College of Physicans & Surgeons, Columbia University, M.D.,1965
University of Pennsylvania, 1972-1987
Multiple Sclerosis and related diseases, Myasthenia Gravis, inflammatory demyelinating neuropathies, inflammatory myopathies, neurologic complications of collagen-vascular diseases, vasculitis
Ragheb, S, Mohamed, M, Lisak, RP. Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the e -subunit of the acetylcholine receptor. J Neuroimmunology 159: 137-145, 2005
Lisak, RP, Benjamins, JA, Bealmear, B, Yao, B, Land, S, Skundric, D. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed gial cell cultures. Mult Scl 12:149-168, 2006
Lisak, RP, Bealmear, B, Benjamins, JA. Secretory products of central nervous system glial cells induce Schwann cell proliferation and protect from cytokine-mediated death. J Neurosci Res 83: 1425-1431, 2006
Ford, CC, Johnson, KP, Lisak, RP, Panitch, HS, Shifroni, G, Wolinsky, JS and The CopaxoneR Study Group. A prospective open-label study of glatiramer acetate: over a decade of continous use in multiple sclerosis patients. Mult Scler 12:309-320, 2006
Lisak, RP, Benjamins, JA, Bealmear, B, Nedelkoska, L, Yao, B, Land, S, Studzinski, D. Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neuronal-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J Neuroinflammation, 4:30, 2007
Lisak, RP, Benajmins, JA. Effects of cytokines and chemokines in Schwann cells: The neuroimmunology of Schwann cells, in Armati, P (ed) The Schwann Cell: An Extraordinary Tale, Cambridge Press, Cambridge, UK, 2007, pp 100-118.
Lisak, RP, Kira, J-Y “Multiple sclerosis” in Lisak, RP, Truong, DD, Carroll, WM, Bhidaysari, R (eds), International Neurology. A Clinical Approach. Wiley-Blackwell, Oxford, UK, 2009, pp366-74, 2009
Ragheb S, Li Y, Simon K, Vanhaerents S, Galimberti D, De Riz M, Fenoglio C, Scarpini E, Lisak R. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler. 2011 Mar 3. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/21372118
Ford, C, Goodman, AD, Johnson, K, Kachuck, N, Lindsey, JW, Lisak, R, Luzzio, C, Myers, L, Panitch, H, Preliningerova, J, Pruitt, A, Rose, J, Rus, H, Wolinsky, J. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 16:342-350, 2010
Goodman, AD, Brown, TR, Edwards, KR, Krupp, LB, Schapiro, RT, Cohen, R, Marinucci, LN, Blight, AR on behalf of the MSF204 Invetigators (Lisak, R WSU site investigator). A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494-502, 2010.
- Phi Beta Kappa
- Fulbright-Hays Senior Research Scholar, United Kingdom
- Fellow, ‘by distinction’ Royal College of Physicians
- Doctors Award, Myasthenia Gravis Foundation of America
- Volunteers Hall of Fame, National Multiple Sclerosis Society
- Advocate of the Year, National Multiple Sclerosis Society, Michigan Chapter
- Founders Day Award, Joseph Smith Honor Society, Helen M Jones Award in History (New York University)
- John Morgan Society, Christian R and Helen F Lindback Foundation Award for Distinguished Teaching (University of Pennsylvania)
- Distinguished Faculty Research Award, Lawrence Weiner Award from the WSU School of Medicine for service to the School of Medicine by a non-alumnus, Wayne State
- University Academy of Scholars, Teacher of the Year Award (presented by the Neurology Residents, WSU/DMC) (Wayne State University)
- Listed in Top Doctors in America, Best Doctors in America, Top Doctors HOUR Detroit Magazine. Who’s Who (multiple)
- Elected a Fellow of the Royal College of Physicians (London) "by distinction" in 2008
- Elected an honorary member of the American Neurological Association 2009
- Awarded Lifetime Achievement Award from the Consortium of Multiple Sclerosis Centers 2011
- In 2011 he was listed as one of the top 1% of physicians in the US by US News and World Report.
- Editor-in-chief for the Journal of the Neurological Sciences 1998-2012
New research funding awarded in 2011
“Effect of ACTH on Glial Cell Function Proliferation and Effects of Cytokines on Gene Regulation.” Sponsor: Questcor Pharmaceuticals, Inc. Robert Lisak, PI, Joyce Benjamins,